

# Basic Drug List Updates

April 2019

TRADE NAME (generic name) or generic name	Brand/Generic Product	Description of Change
ADCIRCA (tadalafil tab 20 mg (pah))	Brand	Removal, Non-Preferred Status, generics available
AIMOVIG (ereenumab-aooe subcutaneous soln auto-injector 70 mg/ml)	Brand	Addition, Preferred Status
ASACOL HD (mesalamine tab delayed release 800 mg)	Brand	Removal, Non-Preferred Status, generics available
CORTIFOAM (hydrocortisone acetate rectal foam 10% (90 mg/dose))	Brand	Removal, Non-Preferred Status
DELSTRIGO (doravirine-lamivudine-tenofovir df tab 100-300-300 mg)	Brand	Addition, Preferred Status
DIVIGEL (estradiol td gel 0.75 mg/0.75gm (0.1%))	Brand	Addition, Preferred Status
EMGALITY (galcanezumab-gnlm subcutaneous soln auto-injector 120 mg/ml)	Brand	Addition, Preferred Status
EMGALITY (galcanezumab-gnlm subcutaneous soln prefilled syr 120 mg/ml)	Brand	Addition, Preferred Status
EPIDIOLEX (cannabidiol soln 100 mg/ml)	Brand	Addition, Preferred Status
GRANIX (tbo-filgrastim subcutaneous inj 300 mcg/ml)	Brand	Addition, Preferred Status
GRANIX (tbo-filgrastim subcutaneous inj 480 mcg/1.6ml (300 mcg/ml))	Brand	Addition, Preferred Status
MITIGARE (colchicine cap 0.6 mg)	Brand	Addition, Preferred Status
NIVESTYM (filgrastim-aafi soln prefilled syringe 300 mcg/0.5ml)	Brand	Addition, Preferred Status
NIVESTYM (filgrastim-aafi soln prefilled syringe 480 mcg/0.8ml)	Brand	Addition, Preferred Status
NOVOLIN 70/30 FLEXPEN (insulin nph & regular susp pen-inj 100 unit/ml (70-30))	Brand	Addition, Preferred Status
NUEDEXTA (dextromethorphan hbr-quinidine sulfate cap 20-10 mg)	Brand	Removal, Non-Preferred Status
ORLISSA (elagolix sodium tab 150 mg (base equiv))	Brand	Addition, Preferred Status
ORLISSA (elagolix sodium tab 200 mg (base equiv))	Brand	Addition, Preferred Status
SYMDEKO (tezacaftor-ivacaftor 100-150 mg & ivacaftor 150 mg tab tbpk)	Brand	Addition, Preferred Status
VIRAMUNE (nevirapine susp 50 mg/5ml)	Brand	Removal, Non-Preferred Status, generics available
WELCHOL (colesevelam hcl packet for susp 3.75 gm)	Brand	Removal, Non-Preferred Status, generics available
XARELTO (rivaroxaban tab 2.5 mg)	Brand	Addition, Preferred Status
ZORTRESS (everolimus tab 1 mg)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.